JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Procita, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Procita, L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 117, Issue 4, 363-373, 1956
Copyright © 1956 by American Society for Pharmacology and Experimental Therapeutics

THE ACTION OF RYANODINE ON MAMMALIAN SKELETAL MUSCLE IX SITU

Leonard Procita 1

1 Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan

Studies have been made of the effect of the highly toxic plant alkaloid, ryanodine, on the isotonic contraction of the cat tibialis aniticus muscle preparation in situ. Small intraarterial injections (50 microgm.) of this alkaloid produce a sustained contracture and rigor of the directly and indirectly stimulated muscle. The ryanodine contracture is abolished or arrested by agents which directly or indirectly diminish the activity of the muscle. Conversely, the contracture is accelerated by agents which directly or indirectly increase the activity of the muscle. In addition, agents which produce anoxia of the muscle and those which have as their own property that of producing a contracture, facilitate the action of ryanodine. Finally ryanodine provides a new and useful experimental tool for the problems concerned with the contraction and relaxation of muscle.

Submitted on February 29, 1956




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
G. Cherednichenko, C. W. Ward, W. Feng, E. Cabrales, L. Michaelson, M. Samso, J. R. Lopez, P. D. Allen, and I. N. Pessah
Enhanced Excitation-Coupled Calcium Entry in Myotubes Expressing Malignant Hyperthermia Mutation R163C Is Attenuated by Dantrolene
Mol. Pharmacol., April 1, 2008; 73(4): 1203 - 1212.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. L. Sutko, J. A. Airey, W. Welch, and L. Ruest
The Pharmacology of Ryanodine and Related Compounds
Pharmacol. Rev., March 1, 1997; 49(1): 53 - 98.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. G. Du, X. Guo, V. K. Khanna, and D. H. MacLennan
Functional Characterization of Mutants in the Predicted Pore Region of the Rabbit Cardiac Muscle Ca2+ Release Channel (Ryanodine Receptor Isoform 2)
J. Biol. Chem., August 17, 2001; 276(34): 31760 - 31771.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1956 by the American Society for Pharmacology and Experimental Therapeutics.